Managing CHAI: From Targeted Therapy to Curative Options

Treatment for CTLA4 haploinsufficiency (CHAI) is highly personalized. Because the disease presents differently in every person, there is no single “correct” path. Instead, your medical team will build a plan that balances two main goals: managing immune dysregulation to stop autoimmunity and protecting you from the infections caused by immunodeficiency ^[1].

Supportive Care: Protecting Against Infection

Since many people with CHAI have low antibody levels (reported as 84% in one cohort) (hypogammaglobulinemia), infection prevention is a cornerstone of care ^[2].

• Immunoglobulin Replacement: This treatment provides your body with the antibodies it cannot make on its own. It is given either as an intravenous infusion (IVIG) in a clinic or as a subcutaneous injection (SCIG) that can often be done at home ^[3][4]. Replacement decisions also consider your individual infection history and specific antibody/vaccine responses.
• Benefits and Limits: While standard replacement therapy is very effective at reducing the number and severity of infections, it does not treat the underlying autoimmunity. It will not shrink swollen lymph nodes or stop the immune system from attacking the gut or lungs ^[5][6].
• Vaccination Plan: Your care team should provide an individualized vaccination plan. Be sure to discuss live vaccines with your specialist, as they may be unsafe or affected by your deficiency and treatments.

Targeted Biological Therapy: Abatacept

An often utilized treatment for CHAI is Abatacept (also known by the brand name Orencia), which is an evidence-supported but often off-label therapy. This is a “pathway-directed” therapy, meaning it is designed to provide a CTLA-4-like blockade ^[7].

• How it Works: Abatacept is a fusion protein that binds to the signaling molecules on other immune cells, preventing them from over-activating your T cells ^[7][8].
• Clinical Success: In a mixed observational cohort of patients with CHAI and LRBA deficiency, approximately 79% of those treated with Abatacept achieved sustained control of their disease ^[9]. Response varies by organ and patient, but it is often effective at controlling gut inflammation (enteropathy), lung disease, and swollen organs ^[10][11].
• Limitations: Abatacept is not a cure and does not reproduce every CTLA-4 function. It manages the symptoms, so it typically requires ongoing, long-term use (route and schedule vary, often given as injections or infusions) ^[10][1].

Other Immunosuppressants

When Abatacept isn’t enough, doctors may use other medications to quiet the overactive immune system:

• Sirolimus (mTOR inhibitor): Often used to manage enlarged organs and some autoimmune symptoms ^[1][6].
• Rituximab: A targeted therapy used specifically to stop the immune system from attacking blood cells (like in ITP or Evans Syndrome) ^[1]. Note that Rituximab can severely worsen antibody deficiency by depleting B-cells.
• Corticosteroids: These are often used for short-term control of severe flares, but they are generally not ideal for long-term use due to side effects ^[12].

Note on Viral Risks: Using these medications can increase the risk of certain viruses waking up, such as EBV (Epstein-Barr Virus) or CMV (Cytomegalovirus). Your doctor will create an individualized monitoring plan, which may include blood tests to monitor these viral levels ^[2][13].

Curative Intent: Hematopoietic Stem Cell Transplant

For patients with severe, life-threatening symptoms that do not respond well to medications, a Hematopoietic Stem Cell Transplant (HSCT) may be a potentially curative option in selected cases ^[14].

HSCT attempts to replace your immune system with healthy cells from a donor ^[1]. However, it is a high-risk procedure and not guaranteed to eliminate every manifestation:

• Survival Rates: A retrospective European cohort study of patients who underwent transplant for CTLA-4 insufficiency or a related deletion showed a 3-year survival rate of approximately 76.7% ^[15].
• Risks: The procedure carries significant risks, including graft failure, organ toxicity, infertility, severe infections, and Graft-versus-Host Disease (GVHD)—where the new immune cells attack the body ^[15][14].
• Timing Matters: Research suggests that transplants are more successful when performed before the disease has caused severe, irreversible organ damage ^[15].

Deciding between ongoing management with medications and a curative transplant is a major decision that involves close collaboration between you, your immunologist, and a transplant specialist ^[16].